Trial Profile

A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
Indications Mantle-cell lymphoma
Focus Therapeutic Use
Acronyms AIM

Most Recent Events

17 Aug 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2025.
01 May 2022 Planned End Date changed from 1 Jun 2018 to 1 Jun 2023.
01 May 2022 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com